Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in previously treated unresectable hepatocellular carcinoma
2017-003983-10Phase 2Unknown
- Sponsor
- BeiGene
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by BeiGene. Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-003983-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003983-10.